Insmed (INSM) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings or view top-rated stocks.

11 analysts have issued 12 month price objectives for Insmed's shares. Their INSM share price forecasts range from $28.00 to $53.00. On average, they predict the company's stock price to reach $43.33 in the next year. This suggests a possible upside of 119.1% from the stock's current price.
View analysts price targets for INSM or view top-rated stocks among Wall Street analysts.

Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM shares have decreased by 1.0% and is now trading at $19.78.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our INSM earnings forecast.

Insmed Incorporated (NASDAQ:INSM) announced its earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($1.08) by $0.09. The biopharmaceutical company earned $65.20 million during the quarter, compared to analyst estimates of $63.93 million. Insmed had a negative net margin of 212.33% and a negative trailing twelve-month return on equity of 3,789.32%. Insmed's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.80) earnings per share.

ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), iShares Biotechnology ETF (IBB), Vanguard Russell 2000 Growth ETF (VTWG) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Insmed updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $285.00 million-$300.00 million, compared to the consensus revenue estimate of $293.16 million.

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.32%), Palo Alto Investors LP (4.32%), Pictet Asset Management SA (2.88%), William Blair Investment Management LLC (2.72%), Suvretta Capital Management LLC (2.15%) and Geode Capital Management LLC (1.92%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends.

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INSM stock can currently be purchased for approximately $19.78.

Insmed (NASDAQ:INSM) has a market capitalization of $2.70 billion and generates $245.36 million in revenue each year. The biopharmaceutical company earns $-481,530,000.00 in net income (profit) each year or ($4.27) on an earnings per share basis.

The company employs 373 workers across the globe.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.